Table 1.
Demographic, clinical and laboratory characteristics of the 5 RRMS patients under ocrelizumab treatment.
| ID | Age | Sex | EDSS | Disease duration (years) | N# of OCRE infusions | Last OCRE COVID-19 (days) | Last OCRE-Sampling (days) | COVID-19 Sampling (days) | COVID-19 Severity | COVID-19 hospital | NPhS-POS NPhS-NEG (Days) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OCRE1 | 33 | M | 0 | 9 | 4 | 184 | 89 | 154 | Mild | No | 7 |
| OCRE2 | 33 | M | 0 | 6 | 3 | 17 | 83 | 66 | Severe | Yes | 31 |
| OCRE3 | 27 | M | 1 | 2 | 5 | 36 | 125 | 89 | Mild | No | 14 |
| OCRE4 | 34 | F | 2.5 | 6 | 4 | 20 | 196 | 176 | Severe | Yes | 25 |
| OCRE5 | 50 | M | 3 | 5 | 5 | 175 | 36 | 85 | Mild | No | 24 |
| ID | Anti-Spike Ab (U/ml) |
CD19% | CD19# cells/µl |
CD3% | CD3# cells/µl |
CD4% | CD4# cells/µl |
CD8% | CD8# cells/µl |
CD4/CD8 ratio | |
| OCRE1 | 0.54 | 0 | 0 | 64.29 | 1337 | 47.3 | 984 | 15.23 | 317 | 3.05 | |
| OCRE2 | <0.40 | 0.08 | 1 | 75.99 | 922 | 38.2 | 464 | 27.54 | 334 | 1.38 | |
| OCRE3 | <0.40 | 0.04 | 1 | 72.74 | 1140 | 35.85 | 562 | 29.54 | 463 | 1.21 | |
| OCRE4 | <0.40 | 0.96 | 15 | 90.88 | 1376 | 53.64 | 812 | 34.19 | 518 | 1.57 | |
| OCRE5 | 155.6 | 0 | 0 | 69.81 | 895 | 48.02 | 615 | 18.47 | 237 | 2.53 | |
Demographic and clinical characteristics of the 5 RRMS patients under ocrelizumab treatment. MS: multiple sclerosis; RR: relapsing-remitting; OCRE: ocrelizumab; Last OCRE COVID-19: days from last ocrelizumab infusion to COVID-19 symptoms onset; Last OCRE Sampling: days from last ocrelizumab infusion to the blood sampling day for T-cell stimulation; COVID-19 Sampling: days from COVID-19 symptom onset to the blood sampling day for T-cell stimulation and anti-Spike antibody quantification; COVID-19 hospital: hospitalization because of COVID-19; NphS-pos NPh-S neg: days from the first SARS-CoV-2 positive nasopharyngeal swab to the first negative nasopharyngeal swab. Ab: antibodies; Anti-Spike Ab limit of detection: 0.40 U/ml